Recursion Pharmaceuticals Inc

Company Profile

Recursion Pharmaceuticals Inc had its IPO on 2021-04-16 under the ticker symbol RXRX.

The company operates in the Healthcare sector and Biotechnology industry. Recursion Pharmaceuticals Inc has a staff strength of 550 employees.

Stock update

Shares of Recursion Pharmaceuticals Inc opened at $8.29 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $8.19 - $8.59, and closed at $8.55.

This is a +2.64% increase from the previous day's closing price.

A total volume of 3,271,293 shares were traded at the close of the day’s session.

In the last one week, shares of Recursion Pharmaceuticals Inc have slipped by -6.25%.

Recursion Pharmaceuticals Inc's Key Ratios

Recursion Pharmaceuticals Inc has a market cap of $1.93 billion, indicating a price to book ratio of 4.46 and a price to sales ratio of 55.9421.

In the last 12-months Recursion Pharmaceuticals Inc’s revenue was $49.99 million with a gross profit of $-164128000 and an EBITDA of $-261298000. The EBITDA ratio measures Recursion Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Recursion Pharmaceuticals Inc’s operating margin was -553.69% while its return on assets stood at -25.83% with a return of equity of -57.36%.

In Q2, Recursion Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 43.6%.

Recursion Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Recursion Pharmaceuticals Inc’s profitability.

Recursion Pharmaceuticals Inc stock is trading at a EV to sales ratio of 46.5949 and a EV to EBITDA ratio of -5.6252. Its price to sales ratio in the trailing 12-months stood at 55.9421.

Recursion Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$666.70 million

Total Liabilities

$113.96 million

Operating Cash Flow

$-2053000.00

Capital Expenditure

$3.97 million

Dividend Payout Ratio

0%

Recursion Pharmaceuticals Inc ended 2024 with $666.70 million in total assets and $0 in total liabilities. Its intangible assets were valued at $666.70 million while shareholder equity stood at $468.96 million.

Recursion Pharmaceuticals Inc ended 2024 with $4.34 million in deferred long-term liabilities, $113.96 million in other current liabilities, 2000.00 in common stock, $-781609000.00 in retained earnings and $60.52 million in goodwill. Its cash balance stood at $405.87 million and cash and short-term investments were $405.87 million. The company’s total short-term debt was $5,895,000 while long-term debt stood at $1.16 million.

Recursion Pharmaceuticals Inc’s total current assets stands at $431.02 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.05 million compared to accounts payable of $2.09 million and inventory worth $3.33 million.

In 2024, Recursion Pharmaceuticals Inc's operating cash flow was $-2053000.00 while its capital expenditure stood at $3.97 million.

Comparatively, Recursion Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$8.55

52-Week High

$16.745

52-Week Low

$4.54

Analyst Target Price

$15.71

Recursion Pharmaceuticals Inc stock is currently trading at $8.55 per share. It touched a 52-week high of $16.745 and a 52-week low of $16.745. Analysts tracking the stock have a 12-month average target price of $15.71.

Its 50-day moving average was $10.46 and 200-day moving average was $8.35 The short ratio stood at 2.69 indicating a short percent outstanding of 0%.

Around 679.6% of the company’s stock are held by insiders while 8892.7% are held by institutions.